COGT insider transaction filings
Cogent Biosciences, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-31. Screen COGT transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing by 1 insider — 45,510 shares, $1,689,493 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
- Largest priced transaction: sale of 42,349 shares @ $37.09 ($1,570,830) by Morris Arlene, filed 2026-08-31.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Morris Arlene — Director | 1 | — | 2 legs · 45,510 sh · $1,689,493 | 4 |
| Ferrante Karen Jean — Director | 1 | — | — | 1 |
Recent Form 4 filings — Cogent Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-31 | 4 | Morris Arlene — Director | Option exercise (M): 41,927 @ $5.64 · Option exercise (M): 3,583 @ $2.52 · Sale (S): 42,349 @ $37.09 · Sale (S): 3,161 @ $37.54 · Option exercise (M): 41,927 (derivative) @ $0 · Option exercise (M): 3,583 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 627 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Shegog Todd — Director | Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Ros Matthew — Director | Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Harwin Peter Evan — Director | Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | CAIN CHRISTOPHER W. — Director | Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Morris Arlene — Director | Grant/award (A): 17,901 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Robbins Andrew R — President and CEO, Director | Gift (G): 160,000 @ $0 · Gift (G): 160,000 @ $0 | EDGAR |
| 2026-04-03 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 686 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | Fairmount Funds Management LLC — Director | Conversion (C): 7,000,000 · Sale (S): 7,000,000 @ $34.66 · Conversion (C): 28,000 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Fairmount Funds Management LLC — Director | Sale (S): 3,500,000 @ $36.40 | EDGAR |
| 2026-01-05 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 643 (derivative) @ $0 | EDGAR |
| 2025-12-30 | 4 | Kearns Evan — Chief Legal Officer | Sale (S): 65,000 @ $38.70 | EDGAR |
| 2025-12-30 | 4 | Green John L. — Chief Financial Officer | Sale (S): 77,000 @ $38.68 | EDGAR |
| 2025-12-30 | 4 | Sachs Jessica — Chief Medical Officer | Sale (S): 82,642 @ $38.70 | EDGAR |
| 2025-12-30 | 4 | Robinson John Edward — Chief Scientific Officer | Sale (S): 90,000 @ $38.74 | EDGAR |
| 2025-12-19 | 4 | Robinson John Edward — Chief Scientific Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 320,000 @ $0 · Tax withholding (F): 139,998 @ $39.45 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Pinnow Cole — Chief Commercial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 214,000 @ $0 · Tax withholding (F): 94,800 @ $39.45 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Sachs Jessica — Chief Medical Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 320,000 @ $0 · Tax withholding (F): 154,716 @ $39.45 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Kearns Evan — Chief Legal Officer | Grant/award (A): 40,000 @ $0 · Grant/award (A): 260,000 @ $0 · Tax withholding (F): 125,602 @ $39.45 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Green John L. — Chief Financial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 300,000 @ $0 · Tax withholding (F): 145,007 @ $39.45 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Robbins Andrew R — President and CEO, Director | Grant/award (A): 185,000 @ $0 · Grant/award (A): 840,000 @ $0 · Tax withholding (F): 367,497 @ $39.45 · Grant/award (A): 245,000 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 1,642 (derivative) @ $0 | EDGAR |
| 2025-07-14 | 4 | Fairmount Funds Management LLC — Director | Purchase (P): 2,777,777 @ $9 | EDGAR |
| 2025-07-02 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 3,314 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | CAIN CHRISTOPHER W. — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Ros Matthew — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Shegog Todd — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Harwin Peter Evan — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Morris Arlene — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 3,788 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Green John L. — Chief Financial Officer | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Pinnow Cole — Chief Commercial Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Robinson John Edward — Chief Scientific Officer | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Sachs Jessica — Chief Medical Officer | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Kearns Evan — Chief Legal Officer | Grant/award (A): 230,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Robbins Andrew R — President and CEO, Director | Grant/award (A): 915,000 (derivative) @ $0 | EDGAR |
| 2025-01-15 | 4 | Pinnow Cole — Chief Commercial Officer | Purchase (P): 43,750 @ $7.60 | EDGAR |
| 2025-01-03 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 2,785 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 2,034 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 2,462 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | CAIN CHRISTOPHER W. — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Ros Matthew — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Harwin Peter Evan — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Shegog Todd — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Ferrante Karen Jean — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Morris Arlene — Director | Grant/award (A): 44,700 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Fairmount Funds Management LLC — Director | Option exercise (M): 1,500,000 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cogent Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=COGT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →